Loading data for RAPP — first visit, this takes a few seconds.

알림

Rapport Therapeutics Inc. (RAPP)

NasdaqGM: RAPP · 실시간 가격 · USD

49.01

+0.59 (1.22%)

종가 기준: Aug 18, 2026, 3:59 PM

49.58

+1.16%

프리마켓: 6:32 AM

1.22% (1D)

매수호가	n/a
시가총액	2.35B
매출 (ttm)	20M
순이익 (ttm)	-137.16M
베타	0.97
EPS (ttm)	-3.03
P/E (ttm)	n/a
선행 P/E	-9.37
P/B (ttm)	5.56
P/S (ttm)	117.57
Earnings Date	Nov 5, 2026

매도호가	n/a
거래량	210,832
평균 거래량 (20일)	353,941
시가	47.81
전일 종가	48.42
일중 범위	47.73 - 49.36
52주 범위	13.90 - 49.50
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

RAPP 소개

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jun 7, 2024

직원 수 84

상장 거래소 NasdaqGM

티커 RAPP

웹사이트 https://www.rapportrx.com

전체 기업 정보

재무 실적

2025년 Rapport Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -111.48M로, 42.37% 증가했습니다.

재무제표

어닝 서프라이즈

Rapport Therapeutics가 Aug 5, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -1.19 예상치 하회 -0.20, 및 -58.67% 전년 대비 감소.

다음 실적 발표

Rapport Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Motley Fool

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?

This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid a year of exceptional stock appreciation.

2개월 전 · Insider Monkey

Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?

Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics,...

2개월 전 · Simply Wall St.

Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?

In late May 2026, analysts BTIG and Truist highlighted Rapport Therapeutics’ RAP-219 program after the company reported progress toward Phase 3 trials, supported by earlier Phase 2a follow-up data. An...

2개월 전 · Insider Monkey

BTIG Raises its Price Target on Rapport Therapeutics (RAPP)

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP)...

3개월 전 · Zacks

Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss

Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the st...

2 페이지 중 1

Rapport Therapeutics Inc. (RAPP)